Sandoz Targets More Than 100 Biosimilars by 2040
Sandoz targets a portfolio of more than 100 biosimilars by 2040.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sandoz unveils Bio 100 strategy to launch 100+ biosimilars by 2040
Company says Bio 100 strategy targets launching over 100 biosimilars by 2040. It aims to double net sales by 2035 and reach a core EBITDA margin above 30%, backed by vertical integration and regulatory streamlining.
Sandoz Bio 100 targets 100+ biosimilars by 2040
Sandoz’s Bio 100 plan targets over 100 biosimilars by 2040, alongside doubling net sales by 2035 and shifting to a biosimilar-led, vertically integrated model.
Sandoz’s Bio100 targets 100+ biosimilars by 2040
Bio100 plans to grow the biosimilar portfolio to over 100 by 2040 and target 80% LoE coverage. It targets mid- to high single-digit sales growth through 2030, doubling net sales by 2035 and core EBITDA margin above 30%.